Medpace Holdings Inc (MEDP) CFO Jesse J. Geiger Sells 25,037 Shares

Medpace Holdings Inc (NASDAQ:MEDP) CFO Jesse J. Geiger sold 25,037 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $60.00, for a total transaction of $1,502,220.00. Following the completion of the transaction, the chief financial officer now directly owns 25,037 shares of the company’s stock, valued at approximately $1,502,220. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

MEDP traded up $0.86 on Friday, reaching $58.71. 234,790 shares of the company’s stock were exchanged, compared to its average volume of 642,650. The firm has a market capitalization of $2.10 billion, a PE ratio of 22.67, a PEG ratio of 1.81 and a beta of 1.62. Medpace Holdings Inc has a twelve month low of $35.00 and a twelve month high of $71.66. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.18.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 25th. The company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.07. Medpace had a net margin of 11.27% and a return on equity of 17.66%. The firm had revenue of $192.12 million for the quarter, compared to analyst estimates of $184.66 million. During the same period in the previous year, the business posted $0.39 earnings per share. Medpace’s quarterly revenue was up 70.5% on a year-over-year basis. As a group, analysts predict that Medpace Holdings Inc will post 2.64 earnings per share for the current fiscal year.

Several research analysts recently issued reports on the stock. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a report on Wednesday, April 10th. ValuEngine lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Zacks Investment Research lowered shares of Medpace from a “hold” rating to a “sell” rating in a research report on Saturday, March 2nd. BidaskClub lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Finally, Wolfe Research started coverage on shares of Medpace in a research report on Tuesday, April 2nd. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $55.33.

Hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its stake in shares of Medpace by 82.2% in the 4th quarter. BlackRock Inc. now owns 4,158,359 shares of the company’s stock valued at $220,103,000 after acquiring an additional 1,876,296 shares during the period. Vanguard Group Inc. raised its stake in shares of Medpace by 63.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after acquiring an additional 1,126,649 shares during the period. Vanguard Group Inc raised its stake in shares of Medpace by 63.6% in the 3rd quarter. Vanguard Group Inc now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after acquiring an additional 1,126,649 shares during the period. Pendal Group Ltd raised its stake in shares of Medpace by 10,018.7% in the 4th quarter. Pendal Group Ltd now owns 1,593,387 shares of the company’s stock valued at $73,338,000 after acquiring an additional 1,577,640 shares during the period. Finally, Laurion Capital Management LP raised its stake in shares of Medpace by 63.1% in the 3rd quarter. Laurion Capital Management LP now owns 1,108,556 shares of the company’s stock valued at $66,414,000 after acquiring an additional 428,785 shares during the period. 82.88% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/jesse-j-geiger-sells-25037-shares-of-medpace-holdings-inc-medp-stock.html.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: How Important is Technical Analysis of Stocks

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.